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Abstract
Background: To evaluate the feasibility of executing a randomized controlled trial of progressive resistance training
(PRT) in women with polycystic ovary syndrome (PCOS).
Methods: Women with PCOS were randomized to an experimental (PRT) group or a no-exercise (usual care)
control group. The PRT group was prescribed two supervised and two unsupervised (home-based) training sessions
per week for 12 weeks. Feasibility outcomes included recruitment and attrition, adherence, adverse events, and
completion of assessments. Secondary outcomes, collected pre and post intervention, included a range of pertinent
physiological, functional and psychological measures.
Results: Fifteen participants were randomised into the PRT group (n = 8) or control group (n = 7); five women
(n = 2 in PRT group and n = 3 in control group) withdrew from the study. The most successful recruitment
sources were Facebook (40 %) and online advertisement (27 %), while least successful methods were referrals
by clinicians, colleagues and flyers. In the PRT group, attendance to supervised sessions was higher (95 %;
standard deviation ±6 %) compared to unsupervised sessions (51 %; standard deviation ±28 %). No adverse
events were attributed to PRT. Change in menstrual cycle status was not significantly different between
groups over time (p = 0.503). However, the PRT group significantly increased body weight (p = 0.01), BMI
(p = 0.04), lean mass (p = 0.01), fat-free mass (p = 0.005) and lower body strength (p = 0.03), while reducing
waist circumference (p = 0.03) and HbA1c (p = 0.033) versus the control group. The PRT group also significantly
improved across several domains of disease-specific and general health-related quality of life, depression,
anxiety and exercise self-efficacy.
Conclusion: A randomized controlled trial of PRT in PCOS would be feasible, and this mode of exercise may
elicit a therapeutic effect on clinically important outcomes in this cohort. The success of a large-scale trial
required to confirm these findings would be contingent on addressing the feasibility hurdles identified in this
study with respect to recruitment, attrition, compliance, and collection of standardized clinical data.
Trial registration: Australia New Zealand Clinical Trials Registry; ACTRN12614000517673 Registered 15 May 2014.
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Background
Polycystic ovary syndrome (PCOS) is a common endo-
crine disease that affects 9-18 % of women [1]. Hyper-
androgenism, menstrual irregularity and polycystic
ovaries define the condition [2], and common features
include insulin resistance, hirsutism, acne, alopecia,
and markers of cardiometabolic disease risk (e.g.
android obesity, inflammation, dyslipidemia, etc.) [3, 4].
PCOS is a leading cause of oligo/anovulation and oligo/
amenorrhea, infertility, and miscarriages [5, 6]. Depression
[7], anxiety [8], body image difficulties [9] and low
health-related quality of life (HRQoL) [10] are common
in this population.
Clinical trials in PCOS have shown that aerobic
training (e.g. cycling, walking) or high-intensity inter-
val training prescribed for 12-24 weeks can signifi-
cantly improve important clinical outcomes, including
insulin sensitivity, body fat percentage, total and LDL-
cholesterol, c-reactive protein (CRP), and psychological
outcomes (e.g. HRQoL and depression) [11–17]. Such
studies have informed clinical practice guidelines, which
recommend that women with PCOS engage in ≥90 min of
aerobic training weekly [18].
Progressive resistance training (PRT) is the most
potent exercise modality for improving skeletal muscle
mass and quality [19, 20]. Notably, studies have consist-
ently shown that PRT can counteract metabolic diseases,
including insulin resistance [20–23]. This is a key
consideration for women with PCOS given that in-
sulin resistance is implicated in the etiology of the
disease [24]. The myogenic adaptations induced by
PRT are often accompanied by a range of phy-
siological (metabolic), functional and psychological
adaptations that may be clinically important in this
cohort [19]. PRT is currently recommended within
exercise prescription guidelines for healthy adults
and those with other major chronic diseases, includ-
ing type 2 diabetes [25–31]. However, PRT is not
currently recommended within clinical practice
guidelines for PCOS [18].
Only two studies to date have investigated the iso-
lated effect of PRT in women with PCOS [32–34].
These studies have shown that chronic PRT (10-16
weeks) can significantly improve several clinically im-
portant outcomes in this cohort, including body com-
position, circulating androgens, blood glucose, sexual
dysfunction, depression and anxiety [32–34]. However,
there is currently a need for additional research on
the safety and efficacy of PRT in PCOS utilizing
robust study designs. Therefore, the purpose of the
present pilot study was to evaluate the feasibility of a
executing a randomized controlled trial (RCT) of PRT




This study randomized participants into an experi-
mental (PRT) group or a no-exercise (usual care)
control group. Randomization assignments were gen-
erated via www.randomization.com by an investigator
not involved in data collection, and given to partici-
pants in sealed envelopes upon the completion of
baseline testing. The Human Research Ethics Commit-
tee at Western Sydney University (reference H10448)
approved all procedures, and written informed consent
was obtained from all participants.
Participants and recruitment
Eligibility Criteria: (1) Age 18-42 years with a diagnosis
of PCOS (confirmed via the participant’s general practi-
tioner or specialist); (2) not currently participating in
PRT; (3) not pregnant nor breastfeeding; (4) no history
of cardiovascular, kidney, respiratory disease, uncon-
trolled hypertension or cancer; (5) no use of cigarettes
for >6 months; (6) no acute or chronic medical condi-
tion that would make assessment and interventions
potentially hazardous or any of the outcomes impossible
to assess; (7) cognition and English language sufficient
to understand research procedures and provide informed
consent; and (8) willingness to be randomised and
undergo study protocols. Participants were recruited by
the lead investigator (L.V.) from February 20 to September
21, 2014 (~7.5 months.). Recruitment was done via flyer
advertisements, social media advertisement (i.e. Facebook),
free online advertisement (i.e. Gumtree), referrals from
local clinicians, word of mouth, referrals by a research
colleague who had conducted PCOS research, and a




Recruitment (or referral) source data was obtained by
asking each potential participant upon initial contact
how she first became aware of the study. One source
was recorded per potential participant. Recruitment
rate was computed by dividing the number of women
randomized by the recruitment period (~7.5 months).
Participant attrition was monitored throughout the
study, and reasons for attrition were sought from all
participants who withdrew.
Adherence
Adherence to the PRT intervention, including super-
vised and home-based components, was recorded using
log-books and computed as the number of sessions
attended divided by the number of sessions offered,
multiplied by 100 %.
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Adverse events
Adverse events in both groups were recorded using a
structured questionnaire administered weekly, in per-
son in the PRT group and via telephone/email in the
control group.
Completion of assessments
The clinical outcomes assessments completed at baseline
(week 0) and follow-up (week 13), and weekly status
checks to monitor adverse events, were recorded for
each participant by the lead investigator (L.V) at the
university campus and/or a private clinic.
Clinical outcomes
Clinical outcomes were assessed prior to and following
the 12-week intervention period (week 0 and 13). Week
13 testing was completed >72 h after the final exercise
session in the PRT group.
Physiological outcomes
Participants retrospectively reported on the duration of
their last menstrual period at baseline (week 0) and that
of their most recent period at follow-up (week 13).
During the study, menstrual cyclicity was self-monitored
by participants using a standardized menstrual diary.
Menstrual cycle was categorized as amenorrhea (no
period for >199 days) [35], oligomenorrhea (cycle
duration of 35 to 199 days) [35] or normal cycle (cycle
duration of 23 to 35 days) [36]. Improvement or worsen-
ing of menstrual cyclicity was defined as a change in the
menstrual cycle category from week 0 to week 13.
Height and weight were measured using calibrated
equipment and standard procedures [37]; body mass
index (BMI) was derived from these measures. Waist
circumference was measured at the level of the umbilicus
[38]. Body composition was analyzed using dual-energy X-
ray absorptiometry (DEXA) as previously described [39];
measurements were obtained for fat mass, lean (muscle)
mass, fat-free mass and body fat percentage.
Blood samples were obtained and analyzed through a
private pathology lab (Douglas Hanly Moir) the morning
following an 8-h overnight fast. Biochemical assays were
obtained for: glycosylated haemoglobin (HbA1c), insulin,
glucose, high-sensitivity C-reactive protein (CRP), testos-
terone, and sex-hormone binding globulin (SHBG) using
standard assays (coefficient of variation (CV): 0.5 % to
6 %). Free androgen index was calculated by [testosterone
(mmol/litre) / SHBG (mmol/litre) x 100], and HOMA-2
was calculated by an online computer model available at
www.OCDEM.ox.ac.uk.
Functional outcomes
Upper and lower body maximum isometric strength was
assessed using triceps extension and knee extension
positions, respectively, using a portable electronic dyna-
mometer (Chatillon DFX-II, AMETEK, Paoli, PA; CV
9.4 %) as previously described [40].
Psychological outcomes
Disease-specific HRQoL was evaluated using the Polycys-
tic Ovary Syndrome Questionnaire (PCOSQ), a 26-item
scale which assesses 5 domains: emotions, body hair,
weight, infertility problems and menstrual problems [41].
Domain scores can range from 1 to 7 with higher scores
representing higher quality of life. The Medical Outcomes
Trust Short Form-36 (SF-36) was used to evaluate eight
domains of general HRQoL (i.e. Physical Functioning,
Role Physical, Bodily Pain, General Health, Vitality, Social
Functioning, Role Emotional and Mental Health) [42].
Higher scores, ranging from 0-100, denote higher HRQoL.
The Depression, Anxiety and Stress Scale 21 (DASS-21)
was used to evaluate symptoms of (1) depression (i.e. hope-
lessness, low self-esteem, and low positive affect) (2)
anxiety (i.e. autonomic arousal, musculoskeletal symp-
toms, situational anxiety and subjective experience of
anxious arousal) and (3) stress (i.e. tension, agitation,
and negative affect). Higher scores in each scale de-
note more severe symptoms. The Exercise Self-Efficacy
Scale was used to measures the self-efficacy of indi-
viduals to undertake physical exercise [43]. Scores can
range from 10 to 40 with higher scores indicating
higher self-efficacy.
Intervention
Participants in the PRT group were prescribed two su-
pervised training sessions per week on non-consecutive
days (i.e. Monday, Wednesday or Friday) for 12 weeks at
the university campus. The PRT group also performed
two home-based (unsupervised) exercise sessions con-
sisting of lower-intensity calisthenics to facilitate habit-
ual movement and behaviour change [44]. Supervised
sessions lasted for approximately 60 min, and included a
standardized (5 min) warm-up and cool-down on exer-
cise cycle or treadmill. PRT exercises included lat pull-
down, leg curl, seated row, leg press, calf raise, chest
press, split squat, shoulder press, biceps curl, triceps
extension and abdominal curl. All sets (except abdom-
inal curl) were performed to neuromuscular fatigue, i.e.
8-12 repetitions maximum; loads were increased with
strength gains. Two sets of each exercise were prescribed
in the first 2 weeks of training. From week 3, all exercises
except split squats and shoulder press were progressed to
3 sets.
The home-based calisthenics exercises were undertaken
on non-PRT days and included lying external hip rotations
(‘clam shells’), side leg raises, push-ups on knees, wall
squats, oblique curls, core stabilization exercises (‘bird
dog’ and abdominal hollowing), performed for 3 sets x 10
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repetitions each. Participants received a different set of
callisthenic home-based exercises every four weeks. Par-
ticipants were asked to record the number of repetitions
of each exercise performed in a log book. This record was
collected weekly.
Control
Participants in the control group did not receive any
PRT intervention and were instructed to continue with
their current lifestyle and usual healthcare and medical
treatments.
Statistical analyses
All available data were included, regardless of patient
compliance to the intervention in an intention-to-treat
analysis, performed using the Statistical Package for the
Social Sciences (IBM© SPSS©, Version 22.0). Data from
patients unavailable for follow-up assessments at week
12 were carried forward from baseline. Baseline charac-
teristics were compared using t-tests and chi-square, as
appropriate. Within group changes over time were eval-
uated by paired t-tests. Group x time effects were deter-
mined by analysis of covariance of the post-treatment
score controlling for the baseline score for all continu-
ous variables, and by chi square for change (improve-
ment or worsening) of menstrual cyclicity. Furthermore,
sensitivity analyses were completed without imputation
of missing data, and using parametric and bootstrap
method (10,000 replicates of the original sample size) to
estimate the effect sizes, and the 95 % confidence inter-





Seventy-eight women contacted the principal investiga-
tor regarding participation and received information
about the study (Fig. 1). Fourteen women were not
reviewed due to their lack of further contact. Sixty-four
women were reviewed for eligibility. Of these women, 25
were deemed ineligible primarily due to living outside
the local region (n = 22) (20 of these women were
referred by Facebook). Thirty-nine women met the eligi-
bility criteria for the study and 20 of them refused
participation with the main reason provided being ‘lack
of time’ (n = 16). Nineteen (n = 19) women consented
and four (n = 4) did not complete baseline testing due to
other commitments (n = 1) or refusal to be randomized
to a no-exercise control group (n = 3). Fifteen women
(n = 15) completed baseline testing and were random-
ized into the PRT group (n = 8) or the control group
(n = 7) resulting in a randomization-to-screening per-
centage of 23 % (15 randomized / 64 reviewed). Of
these women, the main sources of recruitment were
Facebook (n = 6, 40 %) and online advertisement (via
Gumtree) (n = 4, 26.6 %), followed by referrals by local
clinicians (n = 3, 20 %), a research colleague (n = 1, 6.7 %)
and flyers (n = 1, 6.7 %). Two women in the PRT group
and three women in the control group withdrew from the
study and were unavailable for follow-up testing, with
reasons presented in Fig. 1. Two women (one per group)
became pregnant during the trial and were excluded from
analyses due to the confounding effect of pregnancy on
the clinical outcomes. Thirteen women were included in
the statistical analyses. Recruitment rate averaged two
women per month (15 participants / 7.5 months).
Adherence to PRT
Adherence to training inclusive of the two participants
in the PRT group who withdrew from training (Fig. 1)
was 76 % ± 13 % for supervised training, 43 % ± 26 % for
home-based (unsupervised) calisthenics training, and
60 % ± 10 % overall. Excluding these two partici-
pants, attendance was 95 % ± 6 % for supervised
training, 51 % ± 28 % for unsupervised training and
73 % ± 6 % overall.
Adverse events
One participant in the PRT group sustained an ankle
sprain (week 10) from a fall outside of training. This
participant continued to train with two adjustments of
the program to accommodate the injury (i.e. leg press
exercise was performed unilaterally using the non-
affected leg and knee extensions were substituted for the
split squat). Another participant in the PRT group
sustained a lower back injury at work in week 4, which
resulted in withdrawal and inability to complete follow-
up testing (Fig. 1). No adverse events were attributed to
PRT. No adverse events were reported by any participant
in the control group.
Completion of assessments
All participants in the PRT group (n = 5) and control
group (n = 3) available for follow-up testing completed
all clinical outcomes assessments (Fig. 1). All weekly
status checks (100 %) were completed in person by the
PRT group (n = 5), while the control group (via telephone/
email) completed only 58 %.
Baseline characteristics
There were no significant differences between groups at
baseline, according to the descriptive characteristics pre-
sented in Table 1. However, trends were noted for waist
circumference (p = 0.06) and hip circumference (p = 0.10).
The age and BMI of participants ranged from 18-40 years
and 18.3 kg/m2 to 54.6 kg/m2, respectively. In the total
cohort, six participants had oligomenorrhea, four had
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amenorrhea, and three had a regular cycle at baseline.
The most common prescription medication was met-
formin (n = 4 in the PRT group and n = 1 in the control




Menstrual cyclicity improved from baseline in three
women (one in the PRT group and two in the control
group). Menstrual cyclicity worsened in one woman in the
PRT group and remained unchanged in the other nine
women in the study. Change in menstrual cycle status was
not significantly different between groups (p = 0.503).
The PRT group reported a significant increase in body
weight (p = 0.01) and BMI (p = 0.04) compared to the
control group (Table 2). There was also a significant
reduction in waist circumference (p = 0.03) and a signifi-
cant increase in lean mass (p = 0.01) and fat-free mass
(p = 0.005), indicating that the weight gain was due to
muscle hypertrophy. There were no differences in fat
mass or percent body fat between groups over time.
The PRT group reported a significant reduction in HbA1c
over time compared to the control group (p = 0.03).
Unexpectedly, within group analysis revealed that the
PRT group reported a significant increase in fasting
glucose (p = 0.03). No other physiological adaptations
to PRT were noted.
Functional outcomes
The PRT group experienced a trend toward increased
upper body strength (p = 0.06) and a significant increase
Fig. 1 Participant flow chart. *Baseline data carried forward for two participants in the PRT and three participants in the control group that did
not complete follow-up testing. Data for one pregnancy in each group excluded from the analyses
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in lower body strength (p = 0.03) compared to the
control group.
Psychological outcomes
The PRT group significantly improved three of five
PCOSQ domain scores compared to the control group:
emotions (p = 0.003), weight (p = 0.04) and infertility prob-
lems (p = 0.03) versus the control group. In addition, the
PRT group reported a significantly improvement in five of
eight HRQoL (SF-36) domain scores (physical functioning
[p = 0.02], vitality [p = 0.02], social functioning [p = 0.002],
role emotional [p = 0.009] and mental health [p = 0.009)],
two DASS-21 domains (depression [p = 0.01] and anxiety
[p = 0.03]), and exercise self-efficacy (p = 0.04) compared
to the control group. No other psychological group x time
effects were noted.
Post hoc analyses
To determine the effect of higher adherence on the PRT
group, post hoc analyses were performed using data from
participants who completed >75 % of the supervised
sessions (and >60 % of the total training sessions, i.e.
supervised plus home-based) (n = 5). The outcomes of
these analyses did not differ from the primary analyses.
Sensitivity analyses
Group x time analyses were performed without imput-
ation of missing data from participants that did not
undergo final assessment (i.e. per protocol). The outcomes
of these analyses did not differ with the primary analyses,
except that group x time interaction effects for the fol-
lowing outcomes became non-significant: body weight
(p = 0.07), BMI (p = 0.15), and lean mass (p = 0.07).
Using both parametric and bootstrap method, our
result indicated that the confidence intervals of effect
sizes cross each other, indicating that the two methods did
not differ statistically and hence, the effect sizes and their
CI’s for only the parametric method was reported.
Discussion
This pilot study evaluated the feasibility of a PRT
intervention in women with PCOS within an RCT to
inform the development of a robust clinical trial. Our
findings suggest that it is feasible to investigate PRT
in women with PCOS, and that this anabolic inter-
vention may induce a number of clinically important
adaptations.
The study enrolled approximately two participants per
month over 7.5 months. This rate of recruitment is simi-
lar to studies prescribing aerobic training in women with
PCOS (0.5 to 3 women per month) [45–49]. However,
the duration of recruitment in these studies was longer
(8-40 months) resulting in larger sample sizes (n = 20 to
n = 124) [45–49]. Other studies have not stated the
duration of recruitment [14–16, 50–52]. Clearly, partici-
pant recruitment is a challenging aspect of clinical
research [53], and strategies for enhancing recruitment
are therefore important. Our most successful recruitment
methods were the social media platform Facebook (n = 6,
40 %) and online advertisement via Gumtree (n = 4,
26.6 %). The least successful strategies included referral by
local clinicians (n = 3, 20 %), research colleagues (n = 1,
6.7 %) and flyers (n = 1, 6.7 %). Having the support of local
clinicians is essential to fostering participant recruitment
in clinical trials [54]. However, clinicians are often busy
with their own professional duties and may not be able
to offer the level of support required [55]. To foster
recruitment via clinicians, it may be necessary to engage
in regular meetings and/or create more streamlined
pathways for referral.
Table 1 Baseline characteristics of the total cohort and groups
Characteristic Total Cohort (n = 13) PRT Group (n = 7) Control Group (n = 6)
Age (y) 27 (5) 26 (7) 29 (3)
Height (cm) 163.8 (9.3) 168.2 (4.6) 158.7 (11.1)
Body weight (kg) 102.9 (35.0) 117.4 (36.6) 86 (27.0)
Body mass index (kg/m2) 37.8 (11.4) 41.3 (12.5) 34.0 (9.4)
Waist circumference (cm) 110.8 (27.2) 123.6 (29.0) 96.0 (16.3)
Hip circumference (cm) 124.1 (22.1) 133.5 (22.7) 113.0 (17.0)
Waist-to-hip ratio 0.88 (0.09) 0.92 (0.08) 0.85 (0.10)
Systolic blood pressure (mmHg) 116 (9) 114 (8) 118 (10)
Diastolic blood pressure (mmHg) 76 (6) 76 (7) 76 (6)
Menstrual cycle status (n):
Normal cycle 3 2 1
Oligomenorrhea 6 2 4
Amenorrhea 4 3 1
Data reported as mean (standard deviation) except menstrual cycle status (n)
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Table 2 Summary of within and between group changes on clinical outcomes
Outcome Measure PRT (n = 7) Control (n = 6) P (between
groups)
Effect Size
(95 % CI)aWeek 0 Week 12 P Week 0 Week 12 P
Physiological outcomes
Body weight (kg) 117.4 (36.6) 118.9 (35.4) 0.06 86.0 (26.7) 86.0 (26.8) 0.77 0.01 0.49 [0.61,3.83]
Body mass index (kg/m2) 41.3 (12.5) 41.7 (12.1) 0.12 33.8 (9.4) 33.8 (9.4) N/A 0.04 0.37[0.04,1.20]
Waist Circumference (cm) 123.6 (29.0) 121.5 (29.1) 0.04 95.9 (16.3) 96.6 (17.2) 0.20 0.03 0.40b
Fat mass (kg) 58.6 (23.3) 59.0 (22.7) 0.50 39.6 (18.3) 40.6 (19.2) 0.24 0.59 0.03[-2.96,1.79]
Lean mass (kg) 54.7 (12.5) 56.0 (11.3) 0.16 43.9 (10.4) 43.0 (10.0) 0.23 0.01 0.49b
Fat-free mass (kg) 57.4 (13.6) 58.8 (11.9) 0.13 46.8 (10.8) 46.0 (10.4) 0.26 0.005 0.57b
Percent body fat (%) 49.7 (8.4) 49.6 (7.6) 0.84 45.2 (10.7) 46.1 (11.2) 0.22 0.36 0.08[-2.66,1.06]
HbA1c (%) 5.3 (0.4) 5.1 (0.3) 0.037 5.1 (0.3) 5.2 (0.4) 0.24 0.03 0.39b
Fasting insulin (mU/L) 21 (11) 20 (12) 0.49 9 (5) 10 (6) 0.18 0.24 0.14[-5.50,1.55]
Fasting glucose (mmol/L) 4.7 (0.8) 4.9 (0.7) 0.03 4.8 (0.4) 4.9 (0.4) 0.71 0.18 0.17[-0.08,0.40]
HOMA-2 2.62 (1.33) 2.56 (1.43) 0.72 1.19 (0.64) 1.24 (0.71) 0.19 0.27 0.11[-0.65,0.20]
hsCRP (mg/L) 8.9 (10.7) 8.0 (10.8) 0.38 3.6 (5.1) 3.9 (5.4) 0.12 0.36 0.09[-3.57,1.41]
Testosterone (nmol/L) 1.5 (0.3) 1.7 (0.5) 0.38 1.7 (0.4) 1.8 (0.3) 0.11 0.91 0.00[-0.44,0.49]
SHBG (nmol/L) 32 (26) 27 (22) 0.39 47 (25) 47 (25) 0.36 0.25 0.13[-22.58,6.50]
Free androgen index (%) 8.6 (7.3) 9.8 (6.6) 0.26 4.5 (2.7) 4.7 (2.7) 0.11 0.18 0.17[-0.82,3.83]
Functional outcomes
Upper body strength 190.2 (42.5) 211.5 (52.1) 0.10 141.3 (53.0) 134 (51.0) 0.12 0.06 0.33b
Lower body strength 258.7 (67.2) 313.2 (90.3) 0.04 221.8 (59.5) 214.8 (64.9) 0.08 0.03 0.45b
Psychological outcomes
PCOSQ
Emotions 4.4 (0.6) 5.1 (0.5) 0.02 3.2 (1.0) 3.1 (0.9) 0.13 0.003 0.60[0.53,1.95]
Body hair 4.9 (2.0) 4.5 (1.5) 0.37 4.2 (1.7) 4.2 (1.9) 1.0 0.58 0.03[-1.22,0.71]
Weight 3.3(1.7) 4.1(1.7) 0.06 2.4 (1.5) 2.3 (1.5) 0.70 0.04 0.35[0.03,1.796]
Infertility problems 0.9 (0.4) 3.5 (0.9) 0.01 1.1 (0.6) 1.9 (1.2) 0.11 0.03 0.41b
Menstrual problems 4.1 (0.8) 3.9 (0.9) 0.52 3.0 (1.4) 3.0 (1.4) N/A 0.92 0.00[-1.06,0.96]
SF-36
Physical Functioning 83.0 (10.4) 89.3 (12.4) 0.05 94.2 (5.8) 90.8 (10.7) 0.18 0.02 0.42b
Role Physical 21.4 (4.9) 22.3 (3.3) 0.36 17.7 (7.3) 18.8 (7.9) 0.70 0.70 0.02[-4.58,6.58]
Bodily Pain 67.3 (20.0) 65.3 (18.0) 0.55 45.2 (28.3) 48.8 (22.0) 0.36 0.87 0.00[-10.46,9.00]
General Health 49.0 (22.3) 54.3 (25.2) 0.27 53.3 (14.4) 49.2 (10.7) 0.19 0.14 0.20[-3.73,22.58]
Vitality 47.3 (26.2) 56.2 (21.3) 0.12 35.4 (26.4) 30.2 (22.9) 0.29 0.02 0.45b
Social Functioning 75.0 (14.4) 89.3 (15.2) 0.08 60.4 (18.4) 52.1 (9.4) 0.24 0.002 0.64b
Role Emotional 18.0 (5.8) 23.0 (4.1) 0.10 9.7 (8.2) 8.3 (7.5) 0.36 0.009 0.51b
Mental Health 71.4 (22.6) 84.2 (17.2) 0.06 51.7 (20.7) 46.7 (20.7) 0.31 0.009 0.52b
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Although Facebook was our most effective recruitment
method, it also resulted in a large number of ineligible
women contacting the principal investigator. Future stud-
ies conducted within small geographic regions should
consider more targeted methods of advertising via Face-
book (i.e. paid advertisement to more effectively reach the
local community). Alternatively, studies conducted across
multiple geographical sites or countries may benefit from
using Facebook for wider-scale recruitment. No previous
study of exercise in PCOS has noted the use of Facebook
as a recruitment method [14, 16, 45, 48–51].
Our participant attrition rate was 38 % overall (i.e.
29 % (2/7) in the PRT group and 50 % (3/6) in the
control group). Previous studies of exercise training in
PCOS have reported participant attrition rates ranging
from 25 % to 45 % [14, 45, 47–49, 51], while other
studies have not provided these data [46, 48, 52]. In the
present study, two women in the control group were lost
immediately after randomization, while three other
women consented and withdrew from the study given
their concerns about randomization. It has been suggested
that participants who are randomized to a no-treatment
control group, or a treatment group contrary to their
desire, may not accept randomization and refuse partici-
pation [56]. Strategies to minimize participant attrition
may include the use of a placebo-control (i.e. unloaded or
non-progressive training) or a waitlist control group.
Moreover, future studies could opt to investigate the addi-
tive effect of PRT to an exercise intervention prescribed
according to current guidelines which emphasize aerobic
training [17, 18], i.e. by comparing a group receiving
PRT plus aerobic training to a group receiving aerobic
training only.
Attendance to supervised training sessions in the present
study was high (95 ± 6 %). High attendance rates to super-
vised training (>80 %) have been noted in many trials of
aerobic training in PCOS [16, 46, 52]. By comparison,
attendance to the home-based sessions in the present study
was lower (51 %). A previous PCOS study which prescribed
unsupervised exercise (i.e. walking) also demonstrated a
lower compliance rate (43 %) [48]. Studies in other cohorts
have reported both high [57] and low compliance to
home-based training [58]. Potential reasons for low
compliance to home-based exercise prescriptions may
include lack of motivation or time [59]. Future studies
should consider possible strategies to foster adherence
to unsupervised training, including SMS reminders,
effective time management strategies (e.g. diarizing ses-
sions into a routine schedule), motivational cues and
rewards [60–62], and other behavior strategies [63–65].
All reported adverse events were not related to the
study intervention indicating that PRT is safe interven-
tion for women with PCOS. This finding is consistent
with the evidence base in other chronically diseased
cohorts, including type 2 diabetes [66–70].
In general, the completion of clinical outcomes assess-
ments was satisfactory in the present study. However,
the administration of weekly status checks via email and
telephone to monitor adverse events in the control
group proved problematic with only 58 % completed.
This may be improved by arranging weekly visits with
participants, if feasible.
The PRT intervention applied in the present study
yielded a number of clinically important adaptations that
may be associated with better disease management and
treatment of the underlying pathology. No significant
change in menstrual cyclicity was noted in the PRT or
control group. However, studies of aerobic training
[47, 52] and dietary and exercise intervention, includ-
ing those involving aerobic plus PRT [51] have shown
improved menstrual cyclicity using similar methodology
(i.e. self-reported menstrual diary). There is reason to
hypothesize that PRT can improve menstrual cyclicity in
women with PCOS [24]. Therefore, future studies should
continue to investigate this endpoint in women with
oligo/amenorrhea, including the dosages of PRT required
to induce adaptation. Such investigations require vigilant
monitoring of menstrual cycles (i.e. date of last menstrual
period in women with amenorrhea and documenting
menstrual cycle length in women with oligomenorrhea
and regular cycles) and reporting of confounding variables
including physical activity and dietary habits.
Table 2 Summary of within and between group changes on clinical outcomes (Continued)
DASS-21
Depression 10.8 (6.8) 5.4 (5.4) 0.050 12.7 (9.6) 14.7 (9.0) 0.20 0.01 0.50b
Anxiety 10.3 (5.6) 7.4 (7.0) 0.082 12.3 (11.2) 14.3 (10.8) 0.11 0.03 0.41b
Stress 12.6 (7.9) 9.7 (9.3) 0.220 21.7 (10.9) 23.0 (11.2) 0.33 0.17 0.18 [-11.11,2.25]
Exercise Self Efficacy Scale 29.4 (4.7) 31.3 (4.2) 0.095 32.5 (5.3) 30.0 (4.0) 0.10 0.04 0.37b
a = parametric between groups effect sizes and their confidence intervals
b = sample size too small to estimate the confidence intervals
Data reported as mean (standard deviation). Abbreviations: HbA1c hemoglobin A1c, HOMA-2 Homeostatic model of assessment 2, CRP c-reactive protein, SHBG sex
hormone binding globulin, PCOSQ Polycystic Ovary Syndrome Questionnaire, SF-36 Medical Outcomes Trust Short Form-36, DASS-21 Depression, Anxiety and
Stress Scale 21, Effect size = Cohen’s d
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PRT may counteract the etiology of PCOS through its
effect on body composition [24]. Improvements in skeletal
muscle size and quality secondary to PRT in type 2 dia-
betes have been accompanied by reductions in visceral fat
[67, 71] and improvements in insulin sensitivity and glu-
coregulation [67, 71–73]. Increased insulin sensitivity and
glucoregulation, in turn, may downregulate androgen syn-
thesis and hyperandrogenemia in women with PCOS,
which could counteract the disease process (i.e. premature
growth arrest of follicles) and menstrual irregularity [24].
The anthropometric changes experienced by the PRT
group in the present study, including the reduction in
waist circumference (p = 0.03) and increase in fat-free
mass (p = 0.005) were accompanied by an improvement in
HbA1c (p = 0.031) versus the control group, indicating
parallel improvement of body composition and glucoregu-
lation. However, the PRT group experienced no change in
HOMA-2, several key endocrine markers (i.e. free an-
drogen index [p = 0.18], testosterone [p = 0.91], SHBG
[p = 0.246]) or other key haemotological markers asso-
ciated with PCOS (i.e. CRP, fasting insulin) versus the
control group (Table 2). These physiological data are
difficult to interpret within a small-scale study. Future
studies are required to investigate these adaptations,
including the determination of dose-response effects
for each outcome. These studies would also benefit from
using more sensitive measures of insulin resistance, in-
cluding the euglycaemic-hyperinsulaemic clamp [74], and
gold-standard assessment of steroids involving liquid
chromatography-tandem mass spectrometry [75] with the
standardisation of assessments to a particular phase
of the menstrual cycle (i.e. day 2-5 of menstrual
cycle), if required.
Unexpectedly, within group analyses showed that the
PRT group increased fasting glucose over time (p = 0.03).
This finding may be reflective of an acute effect, i.e. in
response to psychological stress or lack of sleep. Previous
studies in PCOS, type 2 diabetes and/or obesity that
prescribed aerobic, mixed training, and/or diet plus exer-
cise have reported significant reductions in fasting insulin
and fasting glucose [46, 47, 52, 76–79] and therefore this
outcome requires further exploration in PCOS.
The PRT group demonstrated a trend toward increased
upper body strength (p = 0.06) and a significant rise in
lower body strength (p = 0.03) compared to the control
group. PRT is the modality of choice for eliciting
strength gains [80, 81] and these adaptations are typ-
ically accompanied by improvements in performance-
based tests and psychological attributes, including
HRQoL [40, 82, 83]. Women with PCOS have been
shown to have greater muscular strength than their
healthy peers [84] and future studies are required to
determine the clinical importance of strength adapta-
tion in this cohort.
The PRT group improved three of five PCOSQ domains
versus the control group: emotions (p = 0.003), weight
(p = 0.04) and infertility problems (p = 0.03). In addition,
the PRT group significantly improved five of eight HRQoL
(SF-36) domain scores (physical functioning [p = 0.02],
vitality [p = 0.02], social functioning [p = 0.002], role emo-
tional [p = 0.009] and mental health [p = 0.009]), DASS-21
domains for depression (p = 0.01) and anxiety (p = 0.03),
and exercise self-efficacy (p = 0.035) versus the control
group. The psychological benefits of exercise or physical
activity in women with PCOS have been noted previously
and are clinically relevant [85, 86]. Future studies involv-
ing placebo-control groups are required to determine if
these psychological adaptations can be attributed solely to
the PRT, or are influenced by the social interaction with
trainers and/or other participants.
Strengths of this study include the collection of feasi-
bility outcomes, and the inclusion of important clinical
outcomes. Limitations of the study included the small
sample size (n = 15) and lack of monitoring and con-
trolling for key confounding variables such as physical
activity and diet.
Conclusion
In summary, a randomized clinical trial of PRT in PCOS
would be feasible to conduct, and this mode of exercise
may elicit a therapeutic effect on a range of pertinent
outcomes in this cohort. A suitably powered clinical trial
is required to confirm these findings and answer novel
research questions in relation to prescribing PRT as a
therapeutic intervention in PCOS. The success of a large-
scale trial required to confirm these findings would be
contingent on addressing the feasibility hurdles identified
in this study with respect to recruitment, attrition, compli-
ance, and collection of standardized clinical data.
Ethics approval and consent to participate
The Human Research Ethics Committee at Western
Sydney University (reference H10448) approved all pro-
cedures, and written informed consent was obtained
from all participants.
Availability of data and materials
The data and materials can be made available on request
via contacting the corresponding author.
Abbreviations
BMI: body mass index; CI: confidence interval; CRP: C-reactive protein;
DASS-21: depression, anxiety and stress scale 21; DEXA: dual-energy X-ray ab-
sorptiometry; HbA1c: glycosylated haemoglobin; HRQoL: health-related
quality of life; PCOS: polycystic ovary syndrome; PCOSQ: polycystic ovary
syndrome questionnaire; PRT: progressive resistance training;
RCT: randomized controlled trial; SF-36: medical outcomes trust short
form-36; SHBG: sex-hormone binding globulin.
Competing interests
The authors declare that they have no competing interests.
Vizza et al. BMC Sports Science, Medicine and Rehabilitation  (2016) 8:14 Page 9 of 12
Authors’ contributions
LV conceived and designed the study, was involved in the acquisition of
data, delivery of intervention and assessments, and drafted the manuscript.
BSC provided consultation regarding the design of the study and statistical
analysis, and contributed to drafting the manuscript. SS and CS provided
clinical and research expertise, interpretation of results, and drafted the
manuscript. KA provided statistical expertise, and contributed to drafting of
the manuscript. All authors have read and approved the final manuscript.
Acknowledgements
We sincerely thank the staff at Western Sydney University Penrith gym for
their support of this study, and Catherine Phillips, Sean Raftry, Kurt Fittler and
Susan Arentz in providing technical support for the study.
Funding
This research was supported by higher degree research funding provided by
Western Sydney University.
Author details
1School of Science and Health, Western Sydney University, Locked Bag 1797,
Penrith, NSW 2751, Australia. 2The National Institute of Complementary
Medicine, Western Sydney University, Penrith, NSW 2751, Australia.
3Department of Endocrinology, Concord Repatriation General Hospital,
Concord West, NSW 2138, Australia.
Received: 29 November 2015 Accepted: 4 May 2016
References
1. March WA, Moore VM, Willson KJ, Phillips DIW, Norman RJ, Davies MJ. The
prevalence of polycystic ovary syndrome in a community sample assessed
under contrasting diagnostic criteria. Hum Reprod. 2010;25(2):544–51.
2. Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Work-shop Group.
Revised 2003 consensus on diagnostic criteria and long-term health risks
related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25.
3. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352(12):1223–36.
4. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. 2007.
5. Giudice LC. Endometrium in PCOS: implantation and predisposition to
endocrine CA. Best Pract Res Clin Endocrinol Metab. 2006;20(2):235–44.
6. Gorry A, White DM, Franks S. Infertility in polycystic ovary syndrome.
Endocrine. 2006;30(1):27–33.
7. Bhattacharya SM, Jha A. Prevalence and risk of depressive disorders in women
with polycystic ovary syndrome (PCOS). Fertil Steril. 2010;94(1):357–9.
8. Deeks AA, Gibson-Helm ME, Teede HJ. Anxiety and depression in polycystic
ovary syndrome: a comprehensive investigation. Fertil Steril. 2010;93(7):2421–3.
9. Himelein MJ, Thatcher SS. Depression and body image among women with
polycystic ovary syndrome. J Health Psychol. 2006;11(4):613–25.
10. Barnard L, Ferriday D, Guenther N, Strauss B, Balen A, Dye L. Quality of life
and psychological well being in polycystic ovary syndrome. Hum Reprod.
2007;22(8):2279–86.
11. Abazar E, Taghian F, Mardanian F, Forozandeh D. Effects of aerobic exercise
on plasma lipoproteins in overweight and obese women with polycystic
ovary syndrome. Adv Biomed Res. 2015;4:68.
12. Haqq L, McFarlane J, Dieberg G, Smart N. The effect of lifestyle intervention
on body composition, glycaemic control and cardio-respiratory fitness in
women with polycystic ovarian syndrome: a systematic review and
meta-analysis. Int J Sport Nutr Exerc Metab. 2014;25(6):533-40.
13. Harrison CL, Lombard CB, Moran LJ, Teede HJ. Exercise therapy in
polycystic ovary syndrome: a systematic review. Hum Reprod Update.
2011;17(2):171–83.
14. Harrison CL, Stepto NK, Hutchison SK, Teede HJ. The impact of intensified
exercise training on insulin resistance and fitness in overweight and obese
women with and without polycystic ovary syndrome. Clin Endocrinol (Oxf).
2012;76(3):351–7.
15. Hutchison S, Teede H, Rachoń D, Harrison C, Strauss B, Stepto N. Effect of
exercise training on insulin sensitivity, mitochondria and computed
tomography muscle attenuation in overweight women with and without
polycystic ovary syndrome. Diabetologia. 2012;55(5):1424–34.
16. Hutchison SK, Stepto NK, Harrison CL, Moran LJ, Strauss BJ, Teede HJ. Effects
of exercise on insulin resistance and body composition in overweight and
obese women with and without polycystic ovary syndrome. J Clin
Endocrinol Metab. 2011;96(1):E48–56.
17. Thomson RL, Buckley JD, Brinkworth GD. Exercise for the treatment and
management of overweight women with polycystic ovary syndrome: a
review of the literature. Obes Rev. 2011;12(5):e202–10.
18. Alliance PA. Evidence Based Guidelines for Assessment and Management of
Polycystic Ovary Syndrome. Melbourne: Jean Hailes Foundation for
Women’s Health on behalf of the PCOS Australian Alliance; 2011.
19. Ciccolo J, Kraemer WJ. Resistance Training for the Prevention and Treatment
of Chronic Disease. Boca Raton: CRC Press; 2013.
20. Tresierras M, Balady G. Resistance training in the treatment of diabetes and
obesity: mechanisms and outcomes. J Cardiopulm Rehabil Prev. 2009;29(2):67–75.
21. Strasser B, Schobersberger W. Evidence for resistance training as a
treatment therapy in obesity. J Obes 2011. doi:10.1155/2011/482564.
22. Strasser B, Siebert U, Schobersberger W. Resistance training in the treatment
of the metabolic syndrome. Sports Med. 2010;40(5):397–415.
23. Sigal R, Kenny G, Boulé N, Wells G, Prud'homme D, Fortier M, Reid R,
Tulloch H, Coyle D, Phillips P et al. Effects of aerobic training, resistance
training, or both on glycemic control in type 2 diabetes. Ann Intern
Med. 2007;147:357–69.
24. Cheema BS, Vizza L, Swaraj S. Progressive resistance training in
polycystic ovary syndrome: can pumping iron improve clinical
outcomes? Sports Med. 2014;44(9):1197-1207.
25. Hordern MD, Dunstan DW, Prins JB, Baker MK, Singh MAF, Coombes JS.
Exercise prescription for patients with type 2 diabetes and pre-diabetes: a
position statement from Exercise and Sport Science Australia. J Sci Med
Sport. 2012;15(1):25–31.
26. Sharman JE, Stowasser M. Australian association for exercise and sports
science position statement on exercise and hypertension. J Sci Med Sport.
2009;12(2):252–7.
27. Hayes S, Spence R, Galvao D, Newton R. Australian Association of Exercise
and Sport Science position stand: Optimising cancer outcomes through
exercise. J Sci Med Sport. 2009;12:428–34.
28. Donnelly J, Blair S, Jakicic J, Manore M, Rankin J, Smith B. American College
of Sports Medicine Position Stand. Appropriate physical activity intervention
strategies for weight loss and prevention of weight regain for adults. Med
Sci Sports Exerc. 2009;41(2):459.
29. Selig SE, Levinger I, Williams AD, Smart N, Holland DJ, Maiorana A, Green DJ,
Hare DL. Exercise & Sports Science Australia Position Statement on exercise
training and chronic heart failure. J Sci Med Sport. 2010;13(3):288–94.
30. Colberg SR, Sigal RJ, Fernhall B, Regensteiner JG, Blissmer BJ, Rubin RR,
Chasan-Taber L, Albright AL, Braun B. Exercise and type 2 diabetes: the
American College of Sports Medicine and the American Diabetes
Association: joint position statement. Diabetes Care. 2010;33(12):e147–167.
31. Kraemer W, Adams K, Cafarelli E, Dudley G, Dooly C, Feigenbaum M, Fleck S,
Franklin B, Fry A, Hoffman J et al. Progression models in resistance training
for healthy adults. Med Sci Sports Exerc. 2002;34(2):364–80.
32. Almenning I, Rieber-Mohn A, Lundgren KM, Shetelig Løvvik T, Garnæs KK,
Moholdt T. Effects of high intensity interval training and strength training
on metabolic, cardiovascular and hormonal outcomes in women with
polycystic ovary syndrome: a pilot study. PLoS One. 2015;10(9):e0138793.
33. Lara LAS, Ramos FKP, Kogure GS, Costa RS, Silva de Sá MF, Ferriani RA, Reis
RM. Impact of Physical Resistance Training on the Sexual Function of
Women with Polycystic Ovary Syndrome. J Sex Med. 2015;12(7):1584-1590.
34. Miranda-Furtado CL, Ramos FKP, Kogure GS, Santana-Lemos BA, Ferriani RA,
Calado RT, dos Reis RM. A nonrandomized trial of progressive resistance
training intervention in women with polycystic ovary syndrome and its
implications in telomere content. Reprod Sci. 2015;23(5):644-54.
35. Fauser BCJM, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R,
Carmina E, Chang J, Yildiz BO, Laven JSE et al. Consensus on women’s
health aspects of polycystic ovary syndrome (PCOS): the Amsterdam
ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil
Steril. 2012;97(1):28–38.e25.
36. De Jonge CJ, Barratt CL. Assisted reproductive technology: accomplishments
and new horizons. Cambridge: University Press; 2002. p. 274.
37. Thompson WR, Gordon NF, Pescatello LS. ACSM’s guidelines for exercise testing
and prescription. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2010.
38. Wessel TR, Arant CB, Olson MB, Johnson BD, Reis SE, Sharaf BL, Shaw LJ,
Handberg E, Sopko G, Kelsey SF. Relationship of physical fitness vs body
mass index with coronary artery disease and cardiovascular events in
women. JAMA. 2004;292(10):1179–87.
Vizza et al. BMC Sports Science, Medicine and Rehabilitation  (2016) 8:14 Page 10 of 12
39. Glickman SG, Marn CS, Supiano MA, Dengel DR. Validity and reliability of
dual-energy X-ray absorptiometry for the assessment of abdominal
adiposity. J Appl Physiol. 2004;97(2):509–14.
40. Cheema B, Abas H, Smith B, O'Sullivan A, Chan M, Patwardhan A, Kelly J,
Gillin A, Pang G, Lloyd B et al. Progressive exercise for anabolism in kidney
disease (PEAK): a randomized, controlled trial of resistance training during
hemodialysis. J Am Soc Nephrol. 2007;18(5):1594–601.
41. Cronin L, Guyatt G, Griffith L, Wong E, Azziz R, Futterweit W, Cook D, Dunaif
A. Development of a health-related quality-of-life questionnaire (PCOSQ) for
women with polycystic ovary syndrome (PCOS) 1. J Clin Endocrinol Metab.
1998;83(6):1976–87.
42. Stewart AL, Greenfield S, Hays RD, Wells K, Rogers WH, Berry SD,
McGlynn EA, Ware JE. Functional status and well-being of patients with
chronic conditions: results from the Medical Outcomes Study. JAMA.
1989;262(7):907–13.
43. Kroll T, Kehn M, Ho P-S, Groah S. The SCI exercise self-efficacy scale
(ESES): development and psychometric properties. Int J Behav Nutr Phys
Act. 2007;4(1):34.
44. Perri MG, Martin AD, Leermakers EA, Sears SF, Notelovitz M. Effects of
group-versus home-based exercise in the treatment of obesity. J Consult
Clin Psychol. 1997;65(2):278.
45. Brown AJ, Setji TL, Sanders LL, Lowry KP, Otvos JD, Kraus WE, Svetkey PL.
Effects of exercise on lipoprotein particles in women with polycystic ovary
syndrome. Med Sci Sports Exerc. 2009;41(3):497–504.
46. Giallauria F, Palomba S, Maresca L, Vuolo L, Tafuri D, Lombardi G, Colao A,
Vigorito C, Francesco O. Exercise training improves autonomic function and
inflammatory pattern in women with polycystic ovary syndrome (PCOS).
Clin Endocrinol (Oxf). 2008;69(5):792–8.
47. Palomba S, Giallauria F, Falbo A, Russo T, Oppedisano R, Tolino A, Colao A,
Vigorito C, Zullo F, Orio F. Structured exercise training programme versus
hypocaloric hyperproteic diet in obese polycystic ovary syndrome
patients with anovulatory infertility: a 24-week pilot study. Hum Reprod.
2008;23(3):642–50.
48. Randeva HS, Lewandowski KC, Drzewoski J, Brooke-Wavell K, O’Callaghan C,
Czupryniak L, Hillhouse EW, Prelevic GM. Exercise decreases plasma total
homocysteine in overweight young women with polycystic ovary
syndrome. J Clin Endocrinol Metab. 2002;87(10):4496–501.
49. Stener-Victorin E, Jedel E, Janson PO, Sverrisdottir YB. Low-frequency
electroacupuncture and physical exercise decrease high muscle
sympathetic nerve activity in polycystic ovary syndrome. Am J Physiol
Regul Integr Comp Physiol. 2009;297(2):R387–95.
50. Bruner B, Chad K, Chizen D. Effects of exercise and nutritional
counseling in women with polycystic ovary syndrome. Appl Physiol
Nutr Metab. 2006;31(4):384–91.
51. Thomson RL, Buckley JD, Noakes M, Clifton PM, Norman RJ, Brinkworth GD.
The effect of a hypocaloric diet with and without exercise training on body
composition, cardiometabolic risk profile, and reproductive function in
overweight and obese women with polycystic ovary syndrome. J Clin
Endocrinol Metab. 2008;93(9):3373–80.
52. Vigorito C, Giallauria F, Palomba S, Cascella T, Manguso F, Lucci R, De
Lorenzo A, Tafuri D, Lombardi G, Colao A et al. Beneficial effects of a
three-month structured exercise training program on cardiopulmonary
functional capacity in young women with polycystic ovary syndrome.
J Clin Endocrinol Metab. 2007;92(4):1379–84.
53. Patel MX, Doku V, Tennakoon L. Challenges in recruitment of research
participants. Adv Psychiatr Treat. 2003;9(3):229–38.
54. Campbell MK, Snowdon C, Francis D, Elbourne D, McDonald AM, Knight R,
Entwistle V, Garcia J, Roberts I, Grant A et al. Recruitment to randomised
trials: strategies for trial enrollment and participation study. The STEPS study.
Health Technol Assess. 2007, 11(48):iii, ix-105.
55. Blanton S, Morris DM, Prettyman MG, McCulloch K, Redmond S, Light KE,
Wolf SL. Lessons learned in participant recruitment and retention: The
EXCITE Trial. Phys Ther. 2006;86(11):1520–33.
56. Smith CA, Pirotta M, Kilbreath S. A feasibility study to examine the role of
acupuncture to reduce symptoms of lymphoedema after breast cancer: a
randomised controlled trial. Acupunct Med. 2014;32(5):387–93.
57. Nelson ME, Layne JE, Bernstein MJ, Nuernberger A, Castaneda C,
Kaliton D, Hausdorff J, Judge JO, Buchner DM, Roubenoff R. The
effects of multidimensional home-based exercise on functional
performance in elderly people. J Gerontol A Biol Sci Med Sci.
2004;59(2):M154–60.
58. Mayoux-Benhamou MA, Roux C, Perraud A, Fermanian J, Rahali-Kachlouf H,
Revel M. Predictors of compliance with a home-based exercise program
added to usual medical care in preventing postmenopausal osteoporosis:
an 18-month prospective study. Osteoporos Int. 2005;16(3):325–31.
59. Johnson CA, Corrigan SA, Dubbert PM, Gramling SE. Perceived barriers to
excercise and weight control practices in community women. Women
Health. 1990;16(3-4):177–91.
60. Chao D, Foy CG, Farmer D. Exercise adherence among older adults: challenges
and strategies. Control Clin Trials. 2000;21(5, Supplement 1):S212–7.
61. Dalle GR, Calugi S, Centis E, El GM, Marchesini G. Cognitive-behavioral
strategies to increase the adherence to exercise in the management of
obesity. J Obes. 2010;2011:348293.
62. Hillsdon M, Thorogood M. A systematic review of physical activity
promotion strategies. Br J Sports Med. 1996;30(2):84–9.
63. Kozica SL, Lombard CB, Ilic D, Ng S, Harrison CL, Teede HJ. Acceptability of
delivery modes for lifestyle advice in a large scale randomised controlled
obesity prevention trial. BMC Public Health. 2015;15:699.
64. Lombard CB, Deeks AA, Ball K, Jolley D, Teede HJ. Weight, physical activity
and dietary behavior change in young mothers: short term results of the
HeLP-her cluster randomized controlled trial. Nutr J. 2009;8:17–7.
65. Teede HJ, Misso ML, Deeks AA, Moran LJ, Stuckey BG, Wong JL, Norman RJ,
Costello MF. Assessment and management of polycystic ovary syndrome:
summary of an evidence-based guideline. Med J Aust. 2011;195(6):S65–112.
66. Benson A, Torode M, Singh MF. The effect of high-intensity progressive
resistance training on adiposity in children: a randomized controlled trial. Int
J Obes (Lond). 2008;32(6):1016–27.
67. Dunstan DW, Daly RM, Owen N, Jolley D, de Courten M, Shaw J, Zimmet P.
High-intensity resistance training improves glycemic control in older
patients with type 2 diabetes. Diabetes Care. 2002;25(10):1729–36.
68. Lemmey AB, Marcora SM, Chester K, Wilson S, Casanova F, Maddison
PJ. Effects of high‐intensity resistance training in patients with
rheumatoid arthritis: A randomized controlled trial. Arthritis Care Res.
2009;61(12):1726–34.
69. Seynnes O, Singh MAF, Hue O, Pras P, Legros P, Bernard PL.
Physiological and functional responses to low-moderate versus
high-intensity progressive resistance training in frail elders.
J Gerontol A Biol Sci Med Sci. 2004;59(5):M503–9.
70. Singh NA, Quine S, Clemson LM, Williams EJ, Williamson DA, Stavrinos TM,
Grady JN, Perry TJ, Lloyd BD, Smith EU. Effects of high-intensity progressive
resistance training and targeted multidisciplinary treatment of frailty on
mortality and nursing home admissions after hip fracture: a randomized
controlled trial. J Am Med Dir Assoc. 2012;13(1):24–30.
71. Gordon B, Benson A, Bird S, et al. Resistance training improves metabolic
health in type 2 diabetes: a systematic review. Diabetes Res Clin Pract. 2009;
83:157–75.
72. Castaneda C, Layne JE, Munoz-Orians L, Gordon PL, Walsmith J, Foldvari M,
Roubenoff R, Tucker KL, Nelson ME. A randomized controlled trial of
resistance exercise training to improve glycemic control in older adults with
type 2 diabetes. Diabetes Care. 2002;25(12):2335–41.
73. Ishii T, Yamakita T, Sato T, Tanaka S, Fujii S. Resistance training improves
insulin sensitivity in NIDDM subjects without altering maximal oxygen
uptake. Diabetes Care. 1998;21(8):1353–5.
74. Stepto NK, Cassar S, Joham AE, Hutchison SK, Harrison CL, Goldstein RF,
Teede HJ. Women with polycystic ovary syndrome have intrinsic insulin
resistance on euglycaemic–hyperinsulaemic clamp. Hum Reprod. 2013.
75. Handelsman D, Wartofsky L. Requirement for mass spectrometry sex steroid
assays in the Journal of Clinical Endocrinology and Metabolism. J Clin
Endocrinol Metab. 2013;98(10):3971–3.
76. Brooks N, Layne JE, Gordon PL, Roubenoff R, Nelson ME, Castaneda-Sceppa
C. Strength training improves muscle quality and insulin sensitivity in
Hispanic older adults with type 2 diabetes. Int J Med Sci. 2007;4(1):19.
77. Kadoglou NP, Iliadis F, Angelopoulou N, Perrea D, Ampatzidis G, Liapis
CD, Alevizos M. The anti-inflammatory effects of exercise training in
patients with type 2 diabetes mellitus. Eur J Cardiovasc Prev Rehabil.
2007;14(6):837–43.
78. Kim ES, Im JA, Kim KC, Park JH, Suh SH, Kang ES, Kim SH, Jekal Y, Lee CW,
Yoon YJ. Improved insulin sensitivity and adiponectin level after exercise
training in obese Korean youth. Obesity. 2007;15(12):3023–30.
79. Yokoyama H, Emoto M, Araki T, Fujiwara S, Motoyama K, Morioka T, Koyama H,
Shoji T, Okuno Y, Nishizawa Y. Effect of aerobic exercise on plasma adiponectin
levels and insulin resistance in type 2 diabetes. Diabetes Care. 2004;27(7):1756–8.
Vizza et al. BMC Sports Science, Medicine and Rehabilitation  (2016) 8:14 Page 11 of 12
80. Braith RW, Stewart KJ. Resistance exercise training: its role in the prevention
of cardiovascular disease. Circulation. 2006;113(22):2642–50.
81. Kraemer WJ, Ratamess NA, French DN. Resistance training for health and
performance. Curr Sports Med Rep. 2002;1(3):165–71.
82. Dunstan D, Puddey I, Beilin L, Burke V, Morton A, Stanton K. Effects of a
short-term circuit weight training program on glycaemic control in NIDDM.
Diabetes Res Clin Pract. 1998;40(1):53–61.
83. Ibañez J, Izquierdo M, Argüelles I, Forga L, Larrión JL, García-Unciti M, Idoate
F, Gorostiaga EM. Twice-weekly progressive resistance training decreases
abdominal fat and improves insulin sensitivity in older men with type 2
diabetes. Diabetes Care. 2005;28(3):662–7.
84. Kogure GS, Silva RC, Picchi Ramos FK, Miranda-Furtado CL, Lara LA, Ferriani
RA, Dos Reis RM. Women with polycystic ovary syndrome have greater
muscle strength irrespective of body composition. Gynecol Endocrinol.
2015;31(3):237–42.
85. Banting LK, Gibson-Helm M, Polman R, Teede HJ, Stepto NK. Physical activity
and mental health in women with Polycystic Ovary Syndrome. BMC
Womens Health. 2014;14(1):1–9.
86. Conte F, Banting L, Teede HJ, Stepto NK. Mental health and physical
activity in women with polycystic ovary syndrome: a brief review.
Sports Med. 2015;45(4):497–504.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Vizza et al. BMC Sports Science, Medicine and Rehabilitation  (2016) 8:14 Page 12 of 12
